FDA Approves OTC Glucose Tracker for Weight Control

On Aug 23, 2025

US FDA Approves Signos Glucose Monitoring System for Weight Management

On August 22, 2025, the U.S. Food and Drug Administration granted clearance to the Signos Glucose Monitoring System. This over-the-counter glucose monitoring system has been developed specifically for weight management.

Integration of Advanced Technology in Signos

Signos incorporates the Stelo by Dexcom glucose biosensor into an artificially intelligent platform. This combination facilitates a comprehensive understanding of the impact of various variables such as food, activity, stress, sleep, and timing on the human body in real-time. As a result, you can make health decisions backed by your own biology and personalized data.

Benefits of the Signos Glucose Monitoring System

The Signos Glucose Monitoring system offers features like personalized metabolic guidance. It fine-tunes this guidance using AI-driven insights. The system helps in improving sleep, managing weight, and lowering the risk of chronic disease. This is achieved by translating real-time glucose fluctuations into simple, personalized recommendations for healthier daily habits and tracking responses to meals, exercise, sleep, and stress.

Subscription Plans and Pricing for Signos

You can subscribe to Signos with a three-month plan priced at $139 per month, or a six-month plan for $129 per month. The company provides all the necessary continuous glucose monitors for the duration of the chosen plan.

Motivation Behind Signos – A Message from the Founder

According to Sharam Fouladgar-Mercer, CEO and founder of Signos, this development signifies much more than a product launch. “Everyone deserves access to insights that help them live healthier, longer, more vibrant lives,” he says. “Signos is not just about data; it’s about giving people ownership over their health and weight journeys in a way never before seen.”